OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
TLRY60

Tilray Brands Inc

PharmaceuticalsVerified

Tilray Brands Inc has a liquidity position that is currently medium, with a current ratio of 2.46 and a negative free cash flow of -$2.08 billion. The company's cash and equivalents stand at $221.67 million, but this is offset by long-term debt of $302.72 million, resulting in a net cash position that is negative. The debt-to-equity ratio is 0.2, indicating a relatively low level of leverage compared to the industry median. Profitability metrics for Tilray are significantly below industry norms, with a return on equity of -1.4468 and a return on assets of -1.0542. The company reported a net loss of $2.19 billion for the period, with operating income also in the red at -$2.28 billion. These figures suggest that the company is not currently generating returns that meet the expectations of its equity and asset base. Tilray's revenue is concentrated in a few key markets, with the United States and Canada being the primary geographic contributors. The company's exposure to these markets is significant, and any regulatory or economic shifts in these regions could have a material impact on its financial performance. The company's segmental breakdown is not fully disclosed, but the focus on cannabis-based products for medical and adult-use markets is a core part of its business model. Looking ahead, Tilray's growth trajectory is uncertain, with the company reporting a revenue of $821.31 million for the period. Analysts have provided a range of price targets, from $6.50 to $24.00, with a mean of $11.04 and a median of $9.50. The mean recommendation is 2.64, indicating a mixed outlook with a slight bias toward caution. The company's ability to achieve positive growth will depend on its capacity to improve profitability and manage its liquidity challenges. The risk assessment for Tilray highlights a medium liquidity risk and a low dilution risk. The company's negative free cash flow and negative net cash position are key liquidity concerns. While the dilution risk is currently low, the company's financial performance and capital structure could change this outlook if it needs to raise additional capital. The risk assessment also notes that the company's net cash is negative after subtracting total debt, which could affect its ability to fund operations and growth initiatives. Recent events and filings indicate that Tilray is navigating a challenging regulatory and market environment. The company's financial performance has been impacted by the highly competitive cannabis industry and the regulatory uncertainties in key markets. Management has been focused on cost optimization and strategic realignment to improve the company's financial position. The company's recent earnings call transcripts and investor relations communications reflect a commitment to long-term value creation despite current financial challenges.

30-day price · TLRY-1.43 (-21.3%)
Low$5.09High$9.34Close$5.29As of22 May, 00:00 UTC
Profile
CompanyTilray Brands Inc
TickerTLRY.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Tilray Brands Inc is a global cannabis and wellness company that develops, produces, and distributes cannabis-based products for medical, adult-use, and wellness markets.

Classification. Tilray is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a confidence level of 0.92.

Tilray Brands Inc has a liquidity position that is currently medium, with a current ratio of 2.46 and a negative free cash flow of -$2.08 billion. The company's cash and equivalents stand at $221.67 million, but this is offset by long-term debt of $302.72 million, resulting in a net cash position that is negative. The debt-to-equity ratio is 0.2, indicating a relatively low level of leverage compared to the industry median. Profitability metrics for Tilray are significantly below industry norms, with a return on equity of -1.4468 and a return on assets of -1.0542. The company reported a net loss of $2.19 billion for the period, with operating income also in the red at -$2.28 billion. These figures suggest that the company is not currently generating returns that meet the expectations of its equity and asset base. Tilray's revenue is concentrated in a few key markets, with the United States and Canada being the primary geographic contributors. The company's exposure to these markets is significant, and any regulatory or economic shifts in these regions could have a material impact on its financial performance. The company's segmental breakdown is not fully disclosed, but the focus on cannabis-based products for medical and adult-use markets is a core part of its business model. Looking ahead, Tilray's growth trajectory is uncertain, with the company reporting a revenue of $821.31 million for the period. Analysts have provided a range of price targets, from $6.50 to $24.00, with a mean of $11.04 and a median of $9.50. The mean recommendation is 2.64, indicating a mixed outlook with a slight bias toward caution. The company's ability to achieve positive growth will depend on its capacity to improve profitability and manage its liquidity challenges. The risk assessment for Tilray highlights a medium liquidity risk and a low dilution risk. The company's negative free cash flow and negative net cash position are key liquidity concerns. While the dilution risk is currently low, the company's financial performance and capital structure could change this outlook if it needs to raise additional capital. The risk assessment also notes that the company's net cash is negative after subtracting total debt, which could affect its ability to fund operations and growth initiatives. Recent events and filings indicate that Tilray is navigating a challenging regulatory and market environment. The company's financial performance has been impacted by the highly competitive cannabis industry and the regulatory uncertainties in key markets. Management has been focused on cost optimization and strategic realignment to improve the company's financial position. The company's recent earnings call transcripts and investor relations communications reflect a commitment to long-term value creation despite current financial challenges.
Key takeaways
  • Tilray Brands Inc is experiencing significant financial losses, with a net loss of $2.19 billion and a negative return on equity of -1.4468.
  • The company's liquidity position is medium, with a current ratio of 2.46 and a negative free cash flow of -$2.08 billion.
  • Tilray's profitability is below industry norms, with a return on assets of -1.0542 and a debt-to-equity ratio of 0.2.
  • The company's revenue is concentrated in the United States and Canada, making it vulnerable to regulatory and economic changes in these markets.
  • Analysts have provided a mixed outlook, with a mean price target of $11.04 and a mean recommendation of 2.64.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$821.3M
Gross profit$240.6M
Operating income-$2.28B
Net income-$2.19B
R&D
SG&A
D&A
SBC
Operating cash flow-$94.6M
CapEx-$32.9M
Free cash flow-$2.08B
Total assets$2.07B
Total liabilities$562.9M
Total equity$1.51B
Cash & equivalents$221.7M
Long-term debt$302.7M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.51B
Net cash-$81.1M
Current ratio2.5
Debt/Equity0.2
ROA-1.1%
ROE-1.4%
Cash conversion4.0%
CapEx/Revenue-4.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricTLRYActivity
Op margin-277.9%7.7% medp25 -2.4% · p75 15.5%bottom quartile
Net margin-266.3%5.9% medp25 -3.8% · p75 12.8%bottom quartile
Gross margin29.3%45.5% medp25 31.1% · p75 62.9%bottom quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-4.0%-7.0% medp25 -14.9% · p75 -3.2%above median
Debt / equity20.0%25.0% medp25 3.8% · p75 63.3%below median
Observations
IR observations
Mean price target11.04 USD
Median price target9.50 USD
High price target24.00 USD
Low price target6.50 USD
Mean recommendation2.64 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count2.00
Hold count8.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.60 USD
Last actual EPS-24.60 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-25 01:01 UTC#53500f72
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 17:47 UTCJob: 038b479e